The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma
High Yield Medical Reviews · 2024
DOI: 10.59707/hymrfhjx7726 ↗Kurz gefasst
Fachartikel in der Zeitschrift High Yield Medical Reviews, 2024. Verfasst von Emaan Haque und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma. CD-19 targeting CAR T-cells have improved outcomes in both aggressive and indolent types of non-Hodgkin lymphoma. Four CAR T-cell products have been approved by the United States (U.S.) Food and Drug Administration (FDA) for the management of non-Hodgkin lymphoma. This article reviews the currently available commercial CAR T-cells products' role in managing diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We summarize pivotal clinical trials and real-world data on their efficacy and safety.
Zitieren
APA
Haque, E., AlKayyat, A., Rios, J., Khosla, M., & Muhsen, I. (2024). The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma. High Yield Medical Reviews. https://doi.org/10.59707/hymrfhjx7726
Vancouver
Haque E, AlKayyat A, Rios J, Khosla M, Muhsen I. The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma. High Yield Medical Reviews. 2024. doi:10.59707/hymrfhjx7726
BibTeX
@article{Haque2024,
author = {Haque, Emaan and AlKayyat, Ahmad and Rios, Jacqueline and Khosla, Meera and Muhsen, Ibrahim},
title = {The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma},
journal = {High Yield Medical Reviews},
year = {2024},
doi = {10.59707/hymrfhjx7726}
}
EUVIMED